portfolio pipelin support wide moat
updat forecast estim
busi strategi outlook
think specialty-market-focus drug portfolio
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim
price data
rate updat
currenc amount express
busi strategi outlook
methodolog valu compani
strategi root merger ms
drug avonex idec cancer drug rituxan rituxan market
penetr alreadi high patent unit state
deriv profit share roch expir
howev think subcutan rituxan well novel
antibodi gazyva allow extend oncolog revenu avonex
longer-act plegridi gener billion annual sale
remain lead ms interferon franchis acquir full
right ms antibodi tysabri billion annual
sale partner howev price power demand
inject ms portfolio slightli erod
gener version teva copaxon launch novel
high-efficaci drug reach market
oral ms drug tecfidera strong launch continu show
solid safeti efficaci data howev continu scrutini
formul patent revok europ
ipr decis valid led us assum
gener entri think vumer licens
could improv gi toler head-to-head data
tecfidera expect like
partial off-set assum total oral ms drug sale
declin howev see signific
royalti roch novel high-efficaci drug ocrevu approv
 europ help off-set pressur
ms franchis
outsid ms strong human genet valid
neurolog pipelin creat potenti off-set ms pressur spinal
muscular atrophi drug spinraza partner ioni reach
billion sale although competit novarti
heel follow aducanumab failur alzheim
think market underestim pipelin includ
continu partnership ioni drug candid treat
condit includ stroke parkinson pain al
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
idec merg combin forc market
multipl sclerosi drug avonex idec cancer drug rituxan today
rituxan next-gener antibodi gazyva market via
collabor roch also market novel ms drug tysabri
tecfidera japan ms portfolio co-promot eisai
hemophilia therapi eloct alprolix partner sobi spun
part bioverativ sever drug candid
phase trial neurolog neurodegen diseas
launch spinraza partner ioni
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
aducanumab failur weigh fve firm
plan lower fair valu estim biogen
follow news phase trial alzheim
drug aducanumab engag emerg
discontinu due futil previous assign
drug probabl approv base strong data
smaller trial drug differenti fail
amyloid antibodi still chanc
drug could work prevent set remov
amyloid antibodi revenu forecast includ
mix data uncertain path
forward pivot trial model expect
action lower fair valu estim
also roll model incorpor pend
nightstar acquisit could modestli sway
valuat rang
continu believ neurolog portfolio
pipelin warrant wide moat rate firm
pipelin see signific progress beyond alzheim
market
pivot trial parkinson phase stroke phase
pain enter phase trigemin neuralgia
program counter expect pressur tecfidera
gener model unit state
spinraza competit novarti zolgensma track
food drug administr approv type spinal
muscular atrophi may
see catalyst vumer ms approv
head-to-head data gastrointestin toler
versu tecfidera tysabri epilepsi data tau antibodi
data progress supranuclear palsi
detail analysi top-lin growth prospect
pipelin candid pleas see healthcar observ
annual drug pipelin report moat remain secur
innov counter price gener headwind
lower fair valu estim
per share follow failur phase
alzheim drug aducanumab valuat impact
partli counter inclus pend acquisit
nightstar bring two ophthalmolog gene therapi
aducanumab valuat
alreadi remov elenbecestat still phase
model continu includ probabl
approv tau antibodi supranuclear palsi
pipelin
spinraza nusinersen think sale peak
billion assum sale begin declin rather
plateau new patient treat spinraza
patient could opt either compet gene therapi
novarti small-molecul therapi roche/ptc
think combin global sale avonex plegridi
continu fall high-single-digit declin annual
new competit expect tysabri declin
billion billion end
forecast jcv-posit patient switch
hit billion assum see roughli
global sale assum gener tecfidera
 off-set total fumar revenu
launch vumer howev base case
assum total fumar sale fall roughli billion
billion assum probabl
approv opicinumab sale billion
year forecast approv
see oper margin
remain rel flat previous declin
royalti manufactur market cost relat
alzheim longer includ model
still model cost spinraza profit-shar
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
 price power may abl counter impact
discontinu seroposit patient new
altern regimen ocrevu long run
scenario think oper margin remain
bull-cas scenario -- valu per
share -- tysabri sale stay flat explicit
forecast period also assum tecfidera
vumer becom domin player ms market
allow secur billion annual sale
assum tecfidera patent hold
vumer see signific gi benefit tecfidera
bear-cas scenario valu per share
assum heavi discontinu new competit
threat weigh tysabri sale global tysabri sale
declin million also forecast minim
 sale tecfidera/vumer assum
gener tecfidera gi benefit vumer
achiev strong profit success
three market product field oncolog
neuroimmunolog introduct tecfidera secur
firm domin share ms market think
barrier entri high potenti biosimilar
product strong strategi
maintain leadership ms price power
strong patient need novel therapi high
pipelin particularli product factor
contribut firm wide moat return invest
capit think averag mid-teen
explicit forecast period easili exceed
estim cost capit
rituxan remain standard care sever form
hematolog cancer collabor revenu receiv
partner roch boost margin
avonex lead interferon therapi ms
long-term safeti record rel conveni
partner ioni vumer royalti payment alkerm
counter ocrevu royalti overal think
top-lin growth averag neg
share-repurchas activ enabl firm achiev
averag earn per share growth period
still rate systemat risk surround share
averag use cost equiti
assumpt align capit cost assumpt
return equiti investor like demand
rel
inelast portfolio ms
treatment tecfidera may see gener competit earli
alzheim drug aducanumab
longer model demonstr high-risk natur
pipelin target base-cas
scenario expect tecfidera/vumer sale fall
around billion also assum tysabri sale
peak billion think new patient add
patient test seroneg jc viru antibodi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
tysabri achiev blockbust sale base outstand
efficaci despit rare seriou side effect think
effort target drug patient least like
experi side effect allow firm see continu
sale despit novel product cleaner safeti profil
howev expect combin sale tecfidera
vumer declin tecfidera billion
billion annual base gener tecfidera
except tecfidera current
blockbust biolog biosimilar competit
loom threat think signific manufactur
develop cost biosimilar maker expect
incur would slow eros sale product
limit number contend abil
compet price data qualiti may also issu
biosimilar first applic avonex biosimilar
reject base insuffici efficaci delay
discontinu rituxan biosimilar push
european launch tysabri like
lower-prior target biosimilar entrant given risk
monitor potenti seriou side effect certain
see moat trend stabl think
introduct new product firm grow
late-stag pipelin off-set new competit
competit price pressur ms oncolog
increas think strong efficaci oral ms therapi
biogen tecfidera novarti gilenya inject
therapi roch launch ocrevu make
less like new patient start older inject
avonex tysabri addit payer
leverag price negoti assum
abl take avonex price increas
roughli annual net basi past sever
year think futur price chang
like closer mid-single-digit increas biogen
recent launch conveni interferon therapi
plegridi littl chang trend opinion
model high-single-digit declin combin
avonex/plegridi tysabri go forward addit
report revenu cancer therapi rituxan
matur biosimilar competit draw
howev think pipelin off-set
pressur older drug roch receiv food drug
administr approv novel effect antibodi
therapi ocrevu relaps ms
compet primari progress ms
approv treatment littl off-label use
current drug add competit
landscap also benefit due roughli
royalti sale two third global
billion ms market exposur new ppm
indic biogen anti-lingo drug candid key part
ms pipelin drug could help repair myelin
sheath coat neuron give novel mechan
action potenti allow patient regain lost
function drug fail hit key endpoint
phase studi saw encourag data
clinic respons opicinumab continu move forward
develop oncolog expect partner
subcutan rituxan also next-gener drug
gazyva launch leukemia product
superior efficaci profil rituxan recent
approv larg indol first-lin lymphoma set
extend oncolog profit stream
individu odd approv mix bullish
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
novel broader neurolog rare-diseas
pipelin includ sever product high risk
spinraza launch annual price
lack treatment option rare deadli diseas
could creat billion market although
assum sale could peak around billion
spinraza begin share market novarti gene
therapi zolgensma divers pipelin follow
spinraza area includ ms next-gener fumar
vumer novel re-myelin therapi opicinumab
al follow
failur aducanumab program alzheim
expect similar fate firm amyloid antibodi
recent failur bace inhibitor
lack differenti elenbecestat reduc
enthusiasm class drug think
tau antibodi could see sale billion
approv treatment supranuclear palsi assum
probabl drug well two
tau-target therapi neurimmun ioni
develop alzheim give exposur
potenti new target diseas
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
lead billion global ms market
avonex plegridi tysabri vumer could improv
tecfidera gi side effect
receiv royalti profit share roch
ms drug ocrevu cancer therapi rituxan
neurolog portfolio outsid ms includ
spinraza therapi sever neurolog
diseas includ parkinson al alzheim
help diversifi revenu boost sale growth
oinject ms therapi avonex lost edg
lead therapi brand oral competit
gener inject launch tysabri risk
profil pml patient jc viru posit
make vulner patient switch roch
aducanumab fail march demonstr
high-risk natur neurolog pipelin
drive growth oral
competit roche/ptc gene therapi novarti
could threaten franchis
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
year-end cash balanc billion free
cash flow billion annual help fund
futur repurchas allow firm flexibl size
futur acquisit firm cash invest
balanc sheet match similar amount debt
matur issu billion
debt help fund share-repurchas program
histor focus return excess cash
sharehold via buyback limit acquisit
collabor record strong expect tuck-in
acquisit go forward billion free cash
flow gener spent vast
major cash repurchas averag
repurchas price per share
profit depend four key blockbust
high-risk potenti high-reward pipelin
physician payer fail support gazyva use
rituxan despit strong superior data leukemia
larg lymphoma set roch could
vulner competit cheaper biosimilar rituxan
 revenu roch
collabor feed directli bottom line boost
margin plegridi like help
maintain lead interferon market expect gener
copaxon weigh sale inject ms therapi
ms portfolio enjoy tremend price
power unit state insur could begin find
way put pressur futur price increas
competitor reach market avonex plegridi
exclud nation formulari
tecfidera sale see slower growth partli due
concern case pml gastrointestin issu
oral drug celgen ozanimod pois
enter market gener version tecfidera could enter
 market success ipr
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
challeng decis expect recent failur
alzheim therapi aducanumab phase trial also
demonstr high-risk natur
chosen area focu within neurolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
capit research manag compani
share
fund
share
fund
scango took ceo juli longtim
execut jame mullen serv ceo
development-stag biotech year
previous spend year bayer scango help
refocu pipelin neurodegen diseas
neurology-rel indic build strong team
neurolog drug discoveri emphas small tuck-in
commerci offic toni kingsley chief doug
left scango depart
begin decis spin firm
hemophilia franchis led specul firm
sale despit turnov chief medic offic alfr
sandrock decad experi support
pipelin current ceo michael vounatso previous
chief commerci offic career
longtim director william young step
role independ chairman replac stelio
papadopoulo chairman regulu
annual meet may overal see
board well qualifi divers independ despit
long tenur sever director applaud
effort emphas restrict stock option
compens packag top execut
believ align interest sharehold howev
take-over defens author prefer stock may
work interest sharehold complex right
agreement partner roch
trigger acquir could damp
enthusiasm potenti acquir
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
aducanumab failur weigh fve firm
plan lower fair valu estim biogen
follow news phase trial alzheim
drug aducanumab engag emerg
discontinu due futil previous assign
drug probabl approv base strong data
smaller trial drug differenti fail
amyloid antibodi still chanc
drug could work prevent set remov
amyloid antibodi revenu forecast includ
mix data uncertain path
forward pivot trial model expect
action lower fair valu estim
also roll model incorpor pend
nightstar acquisit could modestli sway
valuat rang
continu believ neurolog portfolio
pipelin warrant wide moat rate firm
pipelin see signific progress beyond alzheim
market
pivot trial parkinson phase stroke phase
pain enter phase trigemin neuralgia
program counter expect pressur tecfidera
gener model unit state
spinraza competit novarti zolgensma track
food drug administr approv type spinal
muscular atrophi may
see catalyst vumer ms approv
head-to-head data gastrointestin toler
versu tecfidera tysabri epilepsi data tau antibodi
data progress supranuclear palsi
detail analysi top-lin growth prospect
pipelin candid pleas see healthcar observ
annual drug pipelin report moat remain secur
innov counter price gener headwind
franchis stabl pipelin expand jan
report result broadli line
top- bottom-lin expect multipl
sclerosi sale hold slightli better
expect slightli less growth biosimilar
spinraza model model
higher spinraza ms sale well lower
expens top- bottom-lin estim line
manag guidanc howev boost
sg expens long run account multipl
potenti launch neurolog led aducanumab
alzheim maintain fair
valu estim continu believ
neurolog portfolio pipelin warrant wide moat rate
share look under-valued partli due investor
concern outcom phase trial
aducanumab think share look under-valued
regardless aducanumab trial outcom
pipelin see signific progress beyond alzheim
market like ms two midstag remyelin agent
phase pain enter phase trigemin
ms franchis see improv stabil
opinion outsid like inventori drawdown
first quarter think quarter-over-quart growth
remain stabl drain tysabri roch ocrevu
appear lessen delay celgen ozanimod
give tecfidera vumer anoth year rel
minim chang oral ms drug landscap
novarti look pois launch sma gene therapi
zolgensma year think spinraza
continu grow zolgensma like label
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
type infant midteen spinraza growth
line forecast assum averag annual
declin midsingl digit spinraza follow
due zolgensma roch phase oral drug risdiplam
biggest catalyst remain phase aducanumab
data earli continu assign probabl
success also see catalyst
ms approv head-to-head data
epilepsi data tau antibodi
progress supranuclear palsi detail analysi
top-lin growth prospect pipelin candid
pleas see healthcar observ annual drug pipelin
report moat remain secur innov counter
price gener headwind acceler
maintain fve alzheim forecast
despit confus analysi trial oct
eisai present key subset analysi phase studi
eisai amyloid antibodi oct
clinic trial alzheim diseas ctad
meet barcelona make chang
alzheim sale estim
fair valu estim time still assum
billion amyloid antibodi sale amyloid
antibodi approv use probabl
approv drug even remov amyloid
antibodi valuat arriv fair valu
estim near recent trade level addit
valuat factor virtual long-term success
includ tau program think unrealist
still see steadi neurolog focu increasingli
divers portfolio pipelin support wide moat
eisai still discuss idea phase
program regul
uncertainti futur program aducanumab
phase studi fulli enrol final data expect
earli overal think data support conclus
drug target aggreg form amyloid
reduc plaqu burden slow clinic declin high
dose although inconsist subset data
enough prevent us rais assum
probabl approv
updat carrier subset data high-dos
arm versu placebo appear refut idea
imbal carrier high dose arm
placebo arm drove initi posit result juli
reassur gave us confid
efficaci discuss juli note
phase studi strong overal efficaci
data highest dose signific slow
declin measur adcom slower declin
adas-cog slower declin versu placebo trend
benefit cdr-sb slower declin importantli
subset analysi show among placebo patient
carrier non-carri saw declin adcom
composit clinic endpoint use trial
similar one anoth previous discuss
imbal among genet variant
highest dose arm patient carrier
placebo arm patient carrier caus
confus debat surround interpret
howev reassur turn back confus
carrier subset clinic endpoint data suggest
carrier could actual respond better treatment
noncarri would puzzl carrier statu
factor clinic respons aducanumab
patient non-carri group appear slightli
wors placebo cdr-sb chosen primari
endpoint phase studi aducanumab
think small sampl size analysi partli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
due high discontinu rate regulatori action
remov carrier high-dos arm studi
precautionari measur gener variabl
larg base
questionnair make difficult conclud
carrier respond better treatment inclin put
relianc similar reduct plaqu level
much object quantit measur carrier
noncarri high-dos arm
solid third quarter top-lin growth
bottom-lin growth driven multipl sclerosi
franchis stabil growth spinal muscular atrophi
therapi spinraza maintain fair valu
estim subset analysi phase studi eisai
amyloid antibodi present
oct clinic trial alzheim diseas
meet barcelona expect result continu
support safeti efficaci howev
updat data reveal imbal carrier
high-dos arm placebo arm drove
initi posit result juli would expect lower
estim aducanumab histor data vari
significantli among amyloid antibodi base
design two drug differ target bind
still assum billion amyloid antibodi sale
amyloid antibodi approv use
probabl approv drug even remov
amyloid antibodi valuat arriv
fair valu estim near recent trade level
addit valuat factor virtual long-
term success remain early-stag alzheim
pipelin includ tau program think
unrealist beyond oct expect sever key catalyst
culmin final analysi aducanumab
phase alzheim program earli remov
pain drug model follow sciatica trial
failur model includ sale lupu ucb
collabor also recent midstag trial failur
also includ ioni second al program
model remain bullish genet driven
drug develop neurodegen diseas still
see steadi neurolog focu increasingli
divers portfolio pipelin support wide moat
discuss juli note phase studi
strong efficaci data highest dose
signific slow declin measur adcom
slower declin adas-cog slower declin
versu placebo trend benefit cdr-sb
slower declin analysi present oct
includ subgroup analysi clarifi whether
strong efficaci driven imbal among
genet variant highest-dos arm
patient placebo arm patient
clear evid show differ rate declin
patient although
patient tend get diseas
younger age also like experi aria-
 brain swell encourag direct
posit data second-highest dose group
even higher proport patient
placebo group yet still saw posit trend
aducanumab phase data expect earli
stand largest catalyst sever smaller
data readout drive firm time
overal expect pipelin remain
alzheim data earli phase tau antibodi
psp data phase antisens therapi
al data head-to-head data
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
tecfidera data launch data
ophthalmolog gene therapi earli
turn ms sma therapi continu
assum lower-than-consensu revenu long term
due larg competit ms tecfidera tysabri
sale stabil third quarter long run
expect
annual driven competit patient oral
declin price power factor approv
late help see higher
retent rate new fumar patient also potenti
oral competit celgen ozanimod
johnson johnson ponesimod merck
kgaa mavenclad sma drug spinraza
continu grow strongli particularli outsid
assum sale flatten begin declin
novarti gene therapi launch roch
oral therapi risdiplam could launch
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
